Ashland Inc. (ASH) Stock Price & How to Invest

Ashland Inc. is a Wilmington, Delaware based global specialty chemicals company that operates through four segments: Life Sciences (pharma excipients and nutrition), Personal Care (skin, hair, and biofunctionals), Specialty Additives (cellulosic and rheology modifiers used in coatings, construction, and energy), and Intermediates. The company sells performance ingredients rather than commodity chemicals, competing on formulation know-how, regulatory support, and security of supply into consumer and healthcare end markets.

The investment picture in 2026 is a recovery-and-restructuring one. Fiscal 2025 (ended September 2025) revenue fell to roughly $1.82 billion and the company posted a GAAP net loss of about $845 million, driven mainly by non-cash impairments and a business divestiture, while it continued to generate cash and pay a growing dividend. Fiscal 2026 has been steadier: revenue in the June 2026 quarter (fiscal Q3) was about $497 million, up roughly 7% from a year earlier, and adjusted EPS of $1.02 beat the $0.98 consensus. Free cash flow in that quarter was about $103 million, and in September the board approved a new $1 billion share repurchase authorization, double the prior $500 million program. Trailing revenue is about $1.84 billion and trailing free cash flow about $269 million.

Two activist investors (Ancora and Cruiser Capital) publicly pressed the board in mid-2026 to run a formal strategic review and pursue a sale, arguing the standalone company lacks the scale to maximize value. Meanwhile the stock has rerated: at $72.18 it is worth about $3.3 billion, roughly 17x forward earnings and about 11.9x EV/EBITDA, and the fiscal fourth-quarter report is due November 3, 2026, with consensus at about $1.28 of EPS on $502 million of revenue. That makes ASH part operational turnaround, part event-driven catalyst.

Ashland is exposed to cyclical demand in coatings, construction, and energy, and fiscal 2025 showed how destocking can sharply cut volumes and earnings. The large reported net loss reflected impairments and divestiture effects that signal ongoing portfolio and asset-value pressure, and trailing GAAP net income is only about $75 million, which is why the trailing P/E is near 46x even though the forward P/E is about 17x. The dividend payout runs above 100% of trailing GAAP earnings, covered by cash flow rather than reported profit. The activist thesis is uncertain: a sale may not materialize, and a proxy fight could create disruption. Debt of about $1.48 billion against roughly $440 million of cash, input-cost inflation, currency swings, the Hopewell ramp, and the modest scale that activists criticize all weigh on the standalone case. After a 47% one-year gain, analysts' mean target of about $80 sits only modestly above the price, and UBS trimmed its target to $80 from $83 in October 2026.

11 analysts publish price targets on ASH, averaging $79.91 against a $71.19 price as of October 2026, or +12.2%. The published targets run from $70.00 to $90.00, a narrow spread, and the ratings split 9 buy, 3 hold, 0 sell. Over the last six months there have been 8 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ASH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ashland Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Specialty additives and volume recovery. Ashland's Specialty Additives and Life Sciences segments were pressured by destocking and weak coatings and construction demand. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. Ashland is exposed to cyclical demand in coatings, construction, and energy, and fiscal 2025 showed how destocking can sharply cut volumes and earnings. The most pessimistic target, $70.00, is roughly what ASH is worth if this bites instead.

Read the full bull and bear case on ASH, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Ashland Inc. (ASH) has had one share split in the last 10 years:

• 511:250 on May 15, 2017, so every share held became 2.044 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of ASH the day before the 511:250 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ashland Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.84 billion; fiscal Q3 2026 ~$497 million, up ~7%
• Fiscal Q3 2026 EPS: $1.02 adjusted vs ~$0.98 consensus
• Margins (TTM): ~33% gross, ~11.5% operating, ~3% net
• Market cap: ~$3.3 billion at ~$72 per share (Oct 16, 2026)
• P/E: ~46x trailing (GAAP), ~17x forward
• EV/EBITDA: ~11.9x on ~$364 million TTM EBITDA
• Dividend yield: ~2.3% ($1.68 a year)

Trailing GAAP earnings are still depressed by restructuring, so the stock is valued on EBITDA and forward earnings: about 11.9x EV/EBITDA and roughly 17x analysts' fiscal 2027 EPS estimate of $4.29. The 47% one-year rise has pushed the dividend yield down to about 2.3%. The November 3 report (consensus EPS about $1.28) will be the first full-year read since the buyback doubled.

Other names that sit close to ASH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ASH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ASH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ASH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ASH is a turnaround-and-catalyst story: a real specialty chemicals franchise working through soft demand and portfolio cleanup, now returning to growth and buying back stock, while activists press the board to explore a sale. After a 47% one-year run the stock trades near 17x forward earnings.

Whether ASH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ASH a buy or a sell?, and where the stock could go from here in the ASH stock forecast.

For income investors, whether ASH pays a dividend and how the payout looks is covered in does ASH pay a dividend? And to weigh ASH against a peer, read the full side-by-side comparisons: ASH vs IFF and ASH vs WDFC.